Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3 3b Clinical Trials. J of Skin 2024, 8 (4), s404. https://doi.org/10.25251/skin.8.supp.404.